Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort
Identifieur interne : 000D62 ( Main/Exploration ); précédent : 000D61; suivant : 000D63Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort
Auteurs : P. Damier [France] ; F. Viallet [France] ; M. Ziegler [France] ; I. Bourdeix [France] ; K. Rerat [France]Source :
- European Journal of Neurology [ 1351-5101 ] ; 2008-07.
English descriptors
Abstract
Levodopa is the gold standard drug for the symptomatic control of Parkinson’s disease (PD). However, long‐term treatment with conventional formulations [levodopa and a dopa decarboxylase inhibitor (DDCI)], is associated with re‐emergence of symptoms because of wearing‐off and dyskinesia. Treatment with levodopa/DDCI and entacapone extends the half‐life of levodopa, avoiding deep troughs in levodopa plasma levels and providing more continuous delivery of levodopa to the brain. In this open‐label, retrospective, observational study we investigated the effects of levodopa/DDCI and entacapone therapy in 800 PD patients with motor fluctuations. Levodopa/DDCI and entacapone treatment was assessed as good/very good in improving motor fluctuations (64%) and activities of daily living (ADL; 62%). The therapeutic utility was considered to be good/very good in 70% of cases. Moreover, there was a reduction in levodopa dose in 20% of patients. Neurologists preferred levodopa/DDCI and entacapone compared with increasing levodopa dosage, dose‐fractionation or addition of a dopamine agonist (63%, 29% and 23% of patients respectively). Reasons included achieving more continuous dopaminergic stimulation (40%), reducing motor fluctuations (54%) and improving ADL (41%). This analysis reveals the preference of neurologists for levodopa/DDCI and entacapone over conventional levodopa‐modification strategies for the effective treatment of PD motor fluctuations in clinical practice.
Url:
DOI: 10.1111/j.1468-1331.2008.02165.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort</title><author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P." last="Damier">P. Damier</name></author><author><name sortKey="Viallet, F" sort="Viallet, F" uniqKey="Viallet F" first="F." last="Viallet">F. Viallet</name></author><author><name sortKey="Ziegler, M" sort="Ziegler, M" uniqKey="Ziegler M" first="M." last="Ziegler">M. Ziegler</name></author><author><name sortKey="Bourdeix, I" sort="Bourdeix, I" uniqKey="Bourdeix I" first="I." last="Bourdeix">I. Bourdeix</name></author><author><name sortKey="Rerat, K" sort="Rerat, K" uniqKey="Rerat K" first="K." last="Rerat">K. Rerat</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FB1AF7A778E8460826C64B435617CFBBC987FCD1</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1111/j.1468-1331.2008.02165.x</idno><idno type="url">https://api.istex.fr/document/FB1AF7A778E8460826C64B435617CFBBC987FCD1/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001E95</idno><idno type="wicri:Area/Main/Curation">001C04</idno><idno type="wicri:Area/Main/Exploration">000D62</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort</title><author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P." last="Damier">P. Damier</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>INSERM, CIC04, Nantes, France and CHU Nantes, Clinique Neurologique, Nantes</wicri:regionArea><placeName><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Viallet, F" sort="Viallet, F" uniqKey="Viallet F" first="F." last="Viallet">F. Viallet</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service de Neurologie, CH du Pays d’Aix, Aix en Provence</wicri:regionArea><placeName><region type="région">Provence-Alpes-Côte d'Azur</region><settlement type="city">Aix-en-Provence</settlement></placeName></affiliation></author><author><name sortKey="Ziegler, M" sort="Ziegler, M" uniqKey="Ziegler M" first="M." last="Ziegler">M. Ziegler</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Hopital Léopold Belan, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Bourdeix, I" sort="Bourdeix, I" uniqKey="Bourdeix I" first="I." last="Bourdeix">I. Bourdeix</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Novartis Pharma S.A.S, Rueil‐Malmaison Cedex</wicri:regionArea><wicri:noRegion>Rueil‐Malmaison Cedex</wicri:noRegion><wicri:noRegion>Rueil‐Malmaison Cedex</wicri:noRegion></affiliation></author><author><name sortKey="Rerat, K" sort="Rerat, K" uniqKey="Rerat K" first="K." last="Rerat">K. Rerat</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Novartis Pharma S.A.S, Rueil‐Malmaison Cedex</wicri:regionArea><wicri:noRegion>Rueil‐Malmaison Cedex</wicri:noRegion><wicri:noRegion>Rueil‐Malmaison Cedex</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Neurology</title><idno type="ISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2008-07">2008-07</date><biblScope unit="volume">15</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="643">643</biblScope><biblScope unit="page" to="648">648</biblScope></imprint><idno type="ISSN">1351-5101</idno></series><idno type="istex">FB1AF7A778E8460826C64B435617CFBBC987FCD1</idno><idno type="DOI">10.1111/j.1468-1331.2008.02165.x</idno><idno type="ArticleID">ENE2165</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1351-5101</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>activities of daily living</term><term>entacapone</term><term>levodopa</term><term>motor fluctuations</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa is the gold standard drug for the symptomatic control of Parkinson’s disease (PD). However, long‐term treatment with conventional formulations [levodopa and a dopa decarboxylase inhibitor (DDCI)], is associated with re‐emergence of symptoms because of wearing‐off and dyskinesia. Treatment with levodopa/DDCI and entacapone extends the half‐life of levodopa, avoiding deep troughs in levodopa plasma levels and providing more continuous delivery of levodopa to the brain. In this open‐label, retrospective, observational study we investigated the effects of levodopa/DDCI and entacapone therapy in 800 PD patients with motor fluctuations. Levodopa/DDCI and entacapone treatment was assessed as good/very good in improving motor fluctuations (64%) and activities of daily living (ADL; 62%). The therapeutic utility was considered to be good/very good in 70% of cases. Moreover, there was a reduction in levodopa dose in 20% of patients. Neurologists preferred levodopa/DDCI and entacapone compared with increasing levodopa dosage, dose‐fractionation or addition of a dopamine agonist (63%, 29% and 23% of patients respectively). Reasons included achieving more continuous dopaminergic stimulation (40%), reducing motor fluctuations (54%) and improving ADL (41%). This analysis reveals the preference of neurologists for levodopa/DDCI and entacapone over conventional levodopa‐modification strategies for the effective treatment of PD motor fluctuations in clinical practice.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Provence-Alpes-Côte d'Azur</li></region><settlement><li>Aix-en-Provence</li><li>Nantes</li><li>Paris</li></settlement></list><tree><country name="France"><noRegion><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P." last="Damier">P. Damier</name></noRegion><name sortKey="Bourdeix, I" sort="Bourdeix, I" uniqKey="Bourdeix I" first="I." last="Bourdeix">I. Bourdeix</name><name sortKey="Rerat, K" sort="Rerat, K" uniqKey="Rerat K" first="K." last="Rerat">K. Rerat</name><name sortKey="Viallet, F" sort="Viallet, F" uniqKey="Viallet F" first="F." last="Viallet">F. Viallet</name><name sortKey="Ziegler, M" sort="Ziegler, M" uniqKey="Ziegler M" first="M." last="Ziegler">M. Ziegler</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D62 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D62 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:FB1AF7A778E8460826C64B435617CFBBC987FCD1
|texte= Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort
}}
| This area was generated with Dilib version V0.6.23. |  |